Here's what we know about Merck's antiviral drug right now. According to a September report from the Centers for Disease Control and Prevention, unvaccinated people are over 10 times more likely to be hospitalized and die from the disease than fully vaccinated people. While the available COVID-19 vaccines are highly effective, millions of Americans have not been vaccinated.
New data from Johns Hopkins University shows the US has had 49 million confirmed cases and that 789,745 have died from the coronavirus. That's the goal of Merck and Ridgeback in the development of their antiviral pill to fight coronavirus. But if you do get COVID-19, you'll want ways to fight the infection, including the possibility of a pill you can take at home. Vaccines can help check the virus' spread and fend off its most dangerous strains. Merck said its pill can reduce the risk of hospitalization and death by 30% and can be taken orally at home. A COVID pill from Pfizer is also expected to receive FDA approval this year. The US Food and Drug Administration is expected to soon approve the molnupiravir antivirus pill from Merck and Ridgeback Biotherapeutics, following a recommendation last week by an FDA advisory committee for emergency use. For the most up-to-date news and information about the coronavirus pandemic, visit the WHO and CDC websites.Īs the omicron COVID variant spreads across the US, we may soon have more tools to fight off serious infection.
0 kommentar(er)
